AURINIA PHARMACEUTICALS INC (AUPH)
CA05156V1022 - Common Stock
AUPH gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 588 industry peers in the Biotechnology industry. AUPH has a bad profitability rating. Also its financial health evaluation is rather negative. AUPH is valued quite expensive, but it does show an excellent growth.
1. Profitability
1.1 Basic Checks
AUPH had negative earnings in the past year.
AUPH had a negative operating cash flow in the past year.
In the past 5 years AUPH always reported negative net income.
In the past 5 years AUPH always reported negative operating cash flow.
1.2 Ratios
The Return On Assets of AUPH (-14.24%) is better than 87.20% of its industry peers.
The Return On Equity of AUPH (-20.64%) is better than 87.20% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -14.24% | ||
| ROE | -20.64% | ||
| ROIC | N/A |
ROA(3y)-23.51%
ROA(5y)-23.99%
ROE(3y)-28.37%
ROE(5y)-27.98%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
AUPH has a Gross Margin of 91.94%. This is amongst the best in the industry. AUPH outperforms 94.03% of its industry peers.
The Profit Margin and Operating Margin are not available for AUPH so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 91.94% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
AUPH does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for AUPH has been increased compared to 1 year ago.
The number of shares outstanding for AUPH has been increased compared to 5 years ago.
Compared to 1 year ago, AUPH has a worse debt to assets ratio.
2.2 Solvency
AUPH has an Altman-Z score of 0.72. This is a bad value and indicates that AUPH is not financially healthy and even has some risk of bankruptcy.
With a decent Altman-Z score value of 0.72, AUPH is doing good in the industry, outperforming 63.99% of the companies in the same industry.
A Debt/Equity ratio of 0.20 indicates that AUPH is not too dependend on debt financing.
AUPH has a Debt to Equity ratio of 0.20. This is in the lower half of the industry: AUPH underperforms 67.58% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.2 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 0.72 |
ROIC/WACCN/A
WACC7.85%
2.3 Liquidity
A Current Ratio of 5.50 indicates that AUPH has no problem at all paying its short term obligations.
With a Current ratio value of 5.50, AUPH perfoms like the industry average, outperforming 58.53% of the companies in the same industry.
A Quick Ratio of 4.99 indicates that AUPH has no problem at all paying its short term obligations.
AUPH has a Quick ratio (4.99) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 5.5 | ||
| Quick Ratio | 4.99 |
3. Growth
3.1 Past
AUPH shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 28.95%, which is quite impressive.
AUPH shows a strong growth in Revenue. In the last year, the Revenue has grown by 30.94%.
The Revenue has been growing by 222.90% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)28.95%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q-5.56%
Revenue 1Y (TTM)30.94%
Revenue growth 3Y51.88%
Revenue growth 5Y222.9%
Revenue growth Q2Q58.56%
3.2 Future
AUPH is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 34.43% yearly.
Based on estimates for the next years, AUPH will show a very strong growth in Revenue. The Revenue will grow by 24.72% on average per year.
EPS Next Y89.61%
EPS Next 2Y65.71%
EPS Next 3Y60.66%
EPS Next 5Y34.43%
Revenue Next Year28.26%
Revenue Next 2Y28.54%
Revenue Next 3Y28.49%
Revenue Next 5Y24.72%
3.3 Evolution
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for AUPH. In the last year negative earnings were reported.
Also next year AUPH is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
AUPH's earnings are expected to grow with 60.66% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y65.71%
EPS Next 3Y60.66%
5. Dividend
5.1 Amount
AUPH does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
AURINIA PHARMACEUTICALS INC
NASDAQ:AUPH (5/1/2024, 7:00:01 PM)
After market: 5.25 +0.05 (+0.96%)5.2
+0.11 (+2.16%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap752.02M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -14.24% | ||
| ROE | -20.64% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 91.94% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.32
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.2 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 5.5 | ||
| Quick Ratio | 4.99 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)28.95%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y89.61%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)30.94%
Revenue growth 3Y51.88%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y